Current News

Contact | Print version | PDF version | Send article | RSS-Feed

Morphotek Obtains Exclusive License from Micromet for Antibody to Treat Melanoma and Other Cancers

14 Feb 2007 - Micromet, Inc. and Morphotek(R) Inc. announced that Morphotek exercised its option under a 2004 agreement to obtain an exclusive worldwide license for an antibody targeting an antigen with potential activity for the treatment of certain cancers, including melanoma.
 
Under the terms of the agreement, Micromet has received a payment in connection with the exercise of the option by Morphotek and is eligible to receive development milestone payments and royalties on net sales. Morphotek is planning to file an investigational new drug (IND) application later this year and to commence clinical trials in 2008.